Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Santa SP. z o.o

Lodz, 90-302, PolandEU-13 widening countryNot linked to an institution yet

36running trials
19closed trials

The trials here

What the 56 trials at this site are about, from their registry records.

Conditions: Asthma6 trials
Atopic dermatitis (eczema)5 trials
Fatty liver disease (MASLD/MASH)5 trials
Heart failure5 trials
Atrial fibrillation4 trials
Macular degeneration4 trials
Obesity4 trials
Type 2 diabetes4 trials
Epilepsy3 trials
Lupus (SLE)3 trials
Stroke3 trials
Crohn's disease2 trials
and 17 more
Phase: Phase 336 trials
Phase 213 trials
Phase 2/34 trials
Phase 42 trials
Status: Completed18 trials
Recruiting18 trials
Active, not recruiting14 trials
Not yet recruiting4 trials
Suspended1 trial
Terminated1 trial
Lead sponsor: Novo Nordisk A/S5 trials
Boehringer Ingelheim4 trials
AbbVie3 trials
Biohaven Therapeutics Ltd.3 trials
Viatris Innovation GmbH3 trials
and 29 more

Running trials

Not yet recruiting
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
2026-526648-11-00· Phase 2/3· Shenzhen Oculgen Biomedical Technology Co. Ltd.· Source
Recruiting
A Prospective, Randomized, Open-label, Multicentre Study to Compare the Safety of PURETHAL Mites Mixture 50,000 AUeq/mL Rush Up-Dosing Regimen with the Conventional Up-Dosing Regimen in Adult Participants with Allergic House Dust Mite Rhinitis/Rhinoconjunctivitis with or without Asthma.
2026-526908-72-00· Phase 2· HAL Allergy B.V.· Source
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Recruiting
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841· Phase 3· Novo Nordisk A/S· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
2025-524404-29-00· Phase 2· Eli Lilly & Co.· Source
Recruiting
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
NCT07614776· Phase 3· Amgen· Source
Recruiting
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema
2025-522231-34-00· Phase 3· Alvotech Swiss AG· Source
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· Phase 3· Takeda· Source
Active, not recruiting
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· Phase 3· Pfizer· Source
Recruiting
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
NCT07201129· Phase 3· Viatris Innovation GmbH· Source
Active, not recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· Phase 2· UCB Biopharma SRL· Source
Active, not recruiting
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· Phase 3· Pfizer· Source
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188· Phase 3· GlaxoSmithKline· Source
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· Phase 3· GlaxoSmithKline· Source
Recruiting
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
NCT07001800· Phase 2/3· Kardigan, Inc.· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· Phase 3· Takeda· Source
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· Phase 3· Incyte Corporation· Source
Active, not recruiting
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239· Phase 2· Zura Bio Inc· Source
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Enrolling by invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
NCT06475742· Phase 3· Viatris Innovation GmbH· Source
Enrolling by invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source
Active, not recruiting
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· Phase 3· AbbVie· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169· Phase 3· Hoffmann-La Roche· Source
Terminated
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156· Phase 2· Sanofi· Source
Recruiting
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
NCT05943821· Phase 3· Poznan University of Medical Sciences· Source
Active, not recruiting
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576· Phase 3· Viatris Innovation GmbH· Source
Active, not recruiting
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
NCT05636176· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis
2023-507974-42-00· Phase 2· Abivax· Source
Active, not recruiting
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT03811561· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
NCT07430956· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093· Phase 3· Eli Lilly and Company· Source
Completed
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE
NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
NCT06920771· Phase 3· HAL Allergy· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874· Phase 2· Novo Nordisk A/S· Source
Completed
A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
2023-509206-29-00· Phase 3· Rophibio Inc.· Source
Completed
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· Phase 3· Incyte Corporation· Source
Completed
A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain
NCT06379893· Phase 4· HALEON· Source
Completed
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391· Phase 2· Sanofi· Source
Completed
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy
2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Completed
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
NCT05813912· Phase 3· Novo Nordisk A/S· Source
Completed
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580· Phase 4· AbbVie· Source
Completed
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2)
2023-507665-25-00· Phase 3· Areteia Therapeutics Inc.· Source
Active, not recruiting
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600· Phase 3· Areteia Therapeutics· Source
Completed
A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
NCT05656911· Phase 2· Bayer· Source
Completed
Emp-Activity: Empagliflozin Functional Capacity
NCT05350202· Boehringer Ingelheim· Source
Completed
A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration
NCT04757636· Phase 3· Opthea Limited· Source
Completed
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease
2024-511553-22-00· Phase 3· Celgene International II SARL· Source
Completed
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
NCT02782663· Phase 2· AbbVie· Source

Site data: ClinicalTrials.govUpdated 14 Nov 2026

Report an error

Under construction, not live – Santa SP. z o.o: trial site – Frontlight Research